ONCOLife Issues
Featured Articles
Trending Articles
Designing Digital Healthcare Systems for the Future of Patient-Centered Care
Digital Health | 4 March 2026
Novartis Expands US Radioligand Manufacturing With $23 Billion Investment in Florida
Pharma | 9 January 2026
Rewiring RNA: Antisense RNA Therapy Exposes a New Weakness in Pancreatic Cancer
ONCOLife | 8 January 2026
FDA Approves First Subcutaneous Amivantamab Plus Lazertinib for EGFR+ Lung Cancer
FDA & EMA | 18 December 2025
Platinum-Free PADCEV Plus Pembrolizumab Improves Survival in MI Bladder Cancer
Clinical Trials | 18 December 2025
Artificial Intelligence Detects Pancreatic Cancer More Accurately Than Radiologists
AI | 12 December 2025
FDA Approves T-DXd Plus Pertuzumab as a First-Line Standard in HER2+ Breast Cancer
FDA & EMA | 16 December 2025
Less Toxic, More Effective: RW Evidence Supports Reduced Immunotherapy Dose in Melanoma
Clinical Trials | 14 December 2025
Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma
Clinical Trials | 10 December 2025
FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy
FDA & EMA | 12 December 2025
GSK’s ADC Risvutatug Rezetecan Earns FDA Orphan Drug Status for Small Cell Lung Cancer
FDA & EMA | 10 December 2025
Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer
Clinical Trials | 9 December 2025
Lunsumio Combo Deliver High Response Rates in Follicular and Large B-Cell Lymphomas
ONCOLife
8 December 2025
Lung Organoids Offer a Revolutionary Path to Transform Drug Testing and Cancer Therapies
Biotech
2 December 2025
Enozertinib Shows Strong Systemic and CNS Activity in EGFR Exon 20+ NSC Lung Cancer
Clinical Trials
6 December 2025
FDA Approves Durvalumab as First Perioperative Immunotherapy for GEJ Cancers
FDA & EMA
26 November 2025
FDA Approves Keytruda–Padcev Combo as First Perioperative Treatment for Bladder Cancer
FDA & EMA
24 November 2025
Sevabertinib Wins FDA Approval with Strong Responses in HER2+ NSC Lung Cancer
FDA & EMA
20 November 2025
FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma
FDA & EMA
19 November 2025
Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer
ONCOLife
5 November 2025
Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer
ONCOLife
6 November 2025
Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad
Pharma
11 November 2025
Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer
ONCOLife
3 November 2025